Licensing deal gives iOnctura exclusive global development rights to novel TGFβ pathway inhibitor IOA-359 Pipeline expansion builds on iOnctura’s strategy of targeting multiple cancer survival pathways with a single drug; in this case targeting therapy resistance and immune evasion pathways in addition to IOA-359’s direct effects on the tumor Grant will accelerate iOnctura’s preclinical investigation of […]
iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA). Read more…
Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP Competitive Allosteric Modulator Of PI3Kδ, For The Potential Treatment Of Solid And Hematological Tumors Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the publication of non-clinical research on roginolisib in the […]
Each year, Rare Disease Day aims to raise awareness of rare diseases and encourage positive change to patients’ lives. A disease is considered rare when it affects fewer than 1 in 2,000 people and there are 300 million people with rare diseases across the world.1 On Rare Disease Day 2023, we want to celebrate the […]
Updated clinical data demonstrates a prolonged and sustained favorable safety profile for roginolisib (IOA-244) Clinical data shows a comparable safety profile in both solid and hematologic malignancies Clinical responses seen in both solid and hematologic malignancies US FDA grants Orphan Drug Designation for IOA-244 in uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 5 January – iOnctura, a […]
